Venous Leg Ulcer (VLU)
2
Pipeline Programs
3
Companies
3
Clinical Trials
2 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
1
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2024
2025
2026
2027
KerecisIntact Fish Skin Graft
MediWoundEscharEx
ConvaTecConvaVAC™ Ag+ Negative Pressure Wound Therapy System
Clinical Trials (3)
Total enrollment: 216 patients across 3 trials
Evaluating Intact Fish Skin Graft and Standard of Care Versus Standard of Care Alone in Nonhealing Venous Leg Ulcers
Start: Nov 2024Est. completion: Nov 2026
Phase 4Recruiting
A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)
Start: Jun 2025Est. completion: Mar 2027216 patients
Phase 3Recruiting
ConvaVAC™ Ag+ Negative Pressure Wound Therapy System in Chronic Wounds
Start: Jan 2026Est. completion: Oct 2026
N/ANot Yet Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 216 patients
3 companies competing in this space